Basilea Bids Farewell To Oncology To Focus On Anti-Infectives
Puts Faith In US Approval Of Antibiotic Zevtera
Derazantinib, a promising fibroblast growth factor kinase inhibitor, is one of the cancer assets the Swiss firm is preparing to sell off, either separately or in a bundle, as it focuses on anti-infectives.
